Structure Therapeutics, Inc. (GPCR)
35.00
-0.10
(-0.28%)
USD |
NASDAQ |
Sep 18, 16:00
35.11
+0.11
(+0.31%)
After-Hours: 20:00
Structure Therapeutics Enterprise Value : 1.156B for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 1.156B |
| September 17, 2026 | 1.163B |
| September 16, 2026 | 1.192B |
| September 15, 2026 | 1.437B |
| September 14, 2026 | 1.401B |
| September 11, 2026 | 1.417B |
| September 10, 2026 | 1.480B |
| September 09, 2026 | 1.600B |
| September 08, 2026 | 1.539B |
| September 04, 2026 | 2.035B |
| September 03, 2026 | 2.035B |
| September 02, 2026 | 2.068B |
| September 01, 2026 | 2.020B |
| August 31, 2026 | 1.933B |
| August 28, 2026 | 2.037B |
| August 27, 2026 | 2.169B |
| August 26, 2026 | 2.178B |
| August 25, 2026 | 2.219B |
| August 24, 2026 | 2.154B |
| August 21, 2026 | 2.160B |
| August 20, 2026 | 2.261B |
| August 19, 2026 | 2.519B |
| August 18, 2026 | 2.476B |
| August 17, 2026 | 2.492B |
| August 14, 2026 | 2.546B |
| Date | Value |
|---|---|
| August 13, 2026 | 2.559B |
| August 12, 2026 | 2.503B |
| August 11, 2026 | 2.376B |
| August 10, 2026 | 2.495B |
| August 07, 2026 | 2.448B |
| August 06, 2026 | 2.411B |
| August 05, 2026 | 2.262B |
| August 04, 2026 | 2.199B |
| August 03, 2026 | 2.108B |
| July 31, 2026 | 2.085B |
| July 30, 2026 | 2.187B |
| July 29, 2026 | 2.036B |
| July 28, 2026 | 2.074B |
| July 27, 2026 | 2.131B |
| July 24, 2026 | 2.162B |
| July 23, 2026 | 2.281B |
| July 22, 2026 | 2.254B |
| July 21, 2026 | 2.178B |
| July 20, 2026 | 2.009B |
| July 17, 2026 | 2.116B |
| July 16, 2026 | 1.942B |
| July 15, 2026 | 2.197B |
| July 14, 2026 | 2.266B |
| July 13, 2026 | 2.341B |
| July 10, 2026 | 2.464B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.131T |
| Novo Nordisk A/S | 159.23B |
| Pfizer Inc. | 209.43B |
| Johnson & Johnson | 678.48B |
| Merck & Co., Inc. | 409.34B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -106.33M |
| Total Expenses (Quarterly) | 106.33M |
| EPS Diluted (Quarterly) | -1.464 |
| Earnings Yield | -8.80% |
| Normalized Earnings Yield | -9.149 |